Arcus Biosciences, Inc. (NYSE: RCUS) announced on February 18, 2025, that it has entered into an underwriting agreement with Goldman Sachs & Co. LLC and Leerink Partners LLC for the offering, issuance ...

Research analysts at Wedbush issued their FY2029 EPS estimates for shares of Arcus Biosciences in a note issued to investors ...

The news comes on the heels of promising Phase I/Ib data, which point to the potential of casdatifan as a more effective ...

Gilead Sciences has defied analysts’ expectations by passing on its chance to license Arcus Biosciences’ potential rival to Merck & Co.’s kidney cancer drug Welireg.

Arcus Biosciences Inc. (NYSE: RCUS) shares are trading lower Tuesday after the company announced a $150 million common stock ...

One thing we could say about the analysts on Arcus Biosciences, Inc. (NYSE:RCUS) - they aren't optimistic, having just made a major negative revision to their near-term (statutory) forecasts for the ...

Arcus Biosciences shares were down 14%, to $11.33, after the company priced a $150 million stock offering. Shares of the biopharmaceutical company hit their 52-week low of $10.65 earlier in the ...

Arcus Biosciences (RCUS) announced the pricing of an underwritten offering of 13,636,364 shares of its common stock at an offering price of ...

Arcus Biosciences (RCUS) announced that Gilead’s (GILD) time-limited exclusive option rights to casdatifan have expired. In addition, Arcus has ...

The pharma signed an agreement handing PE firm CD&R a 50% stake in its Capella unit. Elsewhere, Gilead and Ultragenyx secured ...

Casdatifan’s progression-free survival benefits could help differentiate it from Merck’s Welireg in the kidney cancer arena, ...